GlassScriptPhysician profile
Qihui Zhai
NPI 1487612743
$5,663.22
in general payments reported to CMS, 2019-2025
11 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Anatomic Pathology provider received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $3,150 · 2021: $1,200 · 2022: $136 · 2023: $327 · 2024: $229 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,676.68 | 2020-2025 | Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $242.32 | 2019-2022 | |
| Tempus Ai, INC | $146.21 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $121.01 | 2019 | |
| Celgene Corporation | $97.35 | 2023-2024 | Reblozyl |
| Lilly USA, LLC | $95.47 | 2023 | |
| Roche Diagnostics Corporation | $87.46 | 2023 | |
| Stemline Therapeutics INC. | $75.99 | 2022 | |
| Astellas Pharma US INC | $73.86 | 2023-2025 | Vyloy |
| Daiichi Sankyo INC. | $24.74 | 2024 | Enhertu |
| Recordati_rare_diseases_inc. | $22.13 | 2024 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qihui Zhai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.